Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion.

Choi, Sung Wook; Kim, Hyun Woong; Yun, Il Han

doi:2010.51.5.707

J Korean Ophthalmol Soc > Volume 51(5); 2010 > Article

Original Article

Journal of the Korean Ophthalmological Society 2010;51(5):707-715.
DOI: https://doi.org/10.3341/jkos.2010.51.5.707 Published online May 15, 2010.

Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion.

Sung Wook Choi, Hyun Woong Kim, Il Han Yun

Department of Ophthalmology, Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea. maekbak@hanmail.net

망막중심정맥폐쇄에서 발생한 황반부종에 대한 유리체강내 베바시주맙 주입술의 효과

최성욱ㆍ김현웅ㆍ윤일한

Department of Ophthalmology, Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea

Abstract

PURPOSE
To report the effect of intravitreal injection of bevacizumab for the treatment of macular edema due to central retinal vein occlusion (CRVO). METHODS: In a retrospective study, 18 consecutive patients (18 eyes) with macular edema from CRVO received intravitreal bevacizumab (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central macular thickness (CMT) at baseline and follow-up visits. Fluorescein angiography was performed during follow-up visits if necessary. Primary outcomes included a change in BCVA and CMT. RESULTS: The mean duration from symptom detection to the first bevacizumab injection was 32.5 days. The patients received a mean of 2.17 injections of bevacizumab per eye. The mean baseline visual acuity (LogMAR) was 1.27 and increased to a mean of 0.75 at 5 weeks, and 0.81 at 24 weeks. The mean central macular thickness at baseline was 640.5 micrometer and decreased to a mean of 295.6 micrometer at 5 weeks and 284.7 micrometer at 24 weeks (p<0.05). In the ischemic CRVO group, no significant changes in visual acuity were found after 24 weeks. The increase in visual acuity did not correlate significantly with the decrease in CMT after 24 weeks (p=0.205). The result from the non-ischemic group was similar to the preceding result (p=0.151). CONCLUSIONS: Intravitreal bevacizumab resulted in a significant decrease in CMT in patients with CRVO after a 6-month follow-up. The visual acuity in patients with non-ischemic CRVO improved, but there was no significant improvement in the ischemic CRVO group.

Key Words: Bevacizumab;Central retinal vein occlusion;Intravitreal injection;Macular edema